• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Poll results: How comfortable are you with including biosimilars in your treatment plans?

Poll

See the results from our recent poll!

Optometry Times asked our audience, "How comfortable are you with including biosimilars in your treatment plans?" and the results are in!

The poll appeared on OptometryTimes.com and was promoted across social channels from Feb. 15 to Feb. 22, 2023.

10 ODs responded:

- 4 said, "Very excited to begin embracing biosimilars"

- 4 said, "Feeling comfortable exploring biosimilar options, though cautiously"

- 0 said, "Still hesitant, I need to learn more about biosimilars"

- 2 said, "With the knowledge of biosimilars I have, I am not comfortable including this in my treatment plans"

To learn more about biosimilars for AMD, check out Euin Cheong, OD's piece on "Introduction to biosimilars for AMD."

Related Videos
Charles Leclercq, CEO of ARxVision, details the new ARx AI headset and its uses
Filomena Ribeiro, MD, PhD, FEBO sits down with Ophthalmology Times Europe to discuss the realities of being a woman in ophthalmology
Marc R Bloomenstein, OD, FAAO, chats with Optometry Times about the benefits of Vevye in the treatment of dry eye
Eric Fazio, OD, talks EVO ICLs versus LASIK for patients in interview with Optometry Times
© 2024 MJH Life Sciences

All rights reserved.